The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

• Published in: Vaccines Vol. 11; no. 7; p. 1181
• Main Authors: Miteva, Dimitrina, Kitanova, Meglena, Batselova, Hristiana, Lazova, Snezhina, Chervenkov, Lyubomir, Peshevska-Sekulovska, Monika, Sekulovski, Metodija, Gulinac, Milena, Vasilev, Georgi V., Tomov, Luchesar, Velikova, Tsvetelina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.06.2023; MDPI
• Subjects: Clinical trials; Coronaviruses; COVID-19; COVID-19 vaccines; Disease prevention; Disease transmission; Effectiveness; efficacy; Enzymes; Genetic diversity; Genetic variance; Genomes; Global health; Immune system; Infections; Medical research; Medicine; Mortality; mRNA vaccines; Mutation; Pandemics; Proteins; Public health; R; Review; safety; SARS-CoV-2 variants; Severe acute respiratory syndrome coronavirus 2; Vaccines; Viral diseases; Viruses; Bulgaria; United Kingdom > UK; Brazil; COVID-19; effectiveness; SARS-CoV-2 variants; vaccines; safety; efficacy
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11071181

Although the chief of the World Health Organization (WHO) has declared the end of the coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a global threat. To be able to manage such pandemics in the future, it is necessary to develop proper strategies and opportunities to protect human life. The data on the SARS-CoV-2 virus must be continuously analyzed, and the possibilities of mutation and the emergence of new, more infectious variants must be anticipated, as well as the options of using different preventive and therapeutic techniques. This is because the fast development of severe acute coronavirus 2 syndrome (SARS-CoV-2) variants of concern have posed a significant problem for COVID-19 pandemic control using the presently available vaccinations. This review summarizes data on the SARS-CoV-2 variants that are responsible for severe COVID-19 and the clinical efficacy of the most commonly used vaccines in clinical practice. The consequences after the disease (long COVID or post-COVID conditions) continue to be the subject of studies and research, and affect social and economic life worldwide.